SCHEMBL30890558

SCHEMBL30890558

[2H]C1N(CCCC)[C@@H](C)CC12OCc1ccccc1NC2=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ OTUD7B Q6GQQ9 1/20 0.43
▸ GAA P10253 2/20 0.33
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ MGAM O43451 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ BRD4 O60885 2/20 0.33
▸ CREBBP Q92793 2/20 0.33
▸ HTR7 P34969 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ SCN9A Q15858 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30890761 0.83 GAA (0.39) GAAPSEN1PSEN2APH1BNCSTN
SCHEMBL30890782 0.71 PDE1A (0.33) OTUD7B
SCHEMBL30890576 0.67 OTUD7B (0.41) OTUD7BGAAALDH1A1
SCHEMBL30890510 0.66 OTUD7B (0.40) OTUD7BPOLBALDH1A1
SCHEMBL27244841 0.62 OTUD7B (0.50) OTUD7BGAABRD4CREBBPHTR7
SCHEMBL20608098 0.62 OTUD7B (0.55) OTUD7BGAABRD4CREBBPPOLB
SCHEMBL27245166 0.61 OTUD7B (0.48) OTUD7BBRD4CREBBPHTR7
SCHEMBL27244771 0.61 OTUD7B (0.46) OTUD7BGAABRD4CREBBPALDH1A1
SCHEMBL20721808 0.60 OTUD7B (1.00) OTUD7B
SCHEMBL7431299 0.58 GRIN1 (0.61) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
Send feedback